Xencor is developing superior monoclonal antibody therapeutics that have been optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. We have seven antibodies in clinical development internally and with partners, including XmAb®5871 in Phase 2a for the treatment of Rheumatoid arthritis and lupus; XmAb®7195 in Phase 1 development for the treatment of asthma; and XmAb®5574/MOR208 which has been licensed to Morphosys and is in Phase 2 for acute lymphoblastic leukemia, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Our XmAb® antibody engineering platform enables us to make subtle changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action, and enhanced performance and market differentiation. These small structural changes augment the interactions that antibodies naturally have with the immune system. We have created a set of enhancements that allow us to increase immune inhibitory activity, extend circulating half-life or enhance cytotoxicity while maintaining 99.5% identity in structure and sequence to natural antibodies. We thereby can avoid the product development challenges of many other next-generation biologics because XmAb antibodies retain the natural antibody structure. Our XmAb technology fuels the growth of our internal pipeline and generates revenues through partnering and licensing.